Psilocybin Mushrooms Gaining Incredible Support Across the U.S.

February 12, 2020 8:45 AM EST | Source: MarijuanaStox

Houston, Texas--(Newsfile Corp. - February 12, 2020) - MarijuanaStox announces publication of an article that discusses The Yield Growth Corporation (CSE: BOSS) (OTCQB: BOSQF). The company has been aggressively addressing demand for health, wellness, and beauty products infused with premium-cannabis and hemp-based products internationally with subsidiary, Urban Juve in addition to psilocybin mushrooms.

Denver, Oakland, and Santa Cruz are Just the First to Legalize

Over the last year, Denver, Colorado, and Oakland, California decriminalized the possession of products containing psilocybin or psilocin.

Then, just weeks ago, the Santa Cruz City Council voted to pass a resolution that decriminalizes psychedelic mushrooms in the city. "Entheogenic plants offer many in our community a way out of the addictive pharmaceuticals known as opioids," said City Councilman Chris Krohn, as quoted by The Hill. "People came forward at last night's meeting telling of the beneficial effects of how these plants changed their lives."

Another city councilman, Drew Glover added, "With the passing of this resolution Santa Cruz has taken an important step in acknowledging the impact that the war on drugs has had on communities while at the same time giving people the liberty to choose how to address their medical needs, providing a potent tool to address issues like PTSD, addiction, and depression."

D.C. may even join those cities this November 2020. In fact, according to The Washington Post, the D.C. Board of Elections decided that the proposal can be placed on the November ballot for a vote. "If approved, the District would join a handful of other cities that have passed similar measures in recent months." However, the proposal must still get a sufficient number of signatures from supporters before it can be added to the ballot officially.

Better, the Decriminalize Nature DC group in D.C. is fighting for the decriminalization of mushrooms. The group is asking that D.C. "cease prosecution of residents of the District of Columbia for non-commercial planting, non-commercial cultivating, purchasing, transporting, distributing, engaging in practices with, and/or possessing entheogenic plants and fungi as defined in D.C. Official Code §5-115.08," as highlighted by WUSA9.

Vermont lawmakers could also decriminalize certain psilocybin. In fact, the Oregon Psilocybin Services Act would allow adults to visit licensed medical facilities to have the psychedelic administered under professional supervision. In order for the initiative to qualify for the November 2020 ballot, 112,020 signatures must be collected by July 2.

Even better, Marijuanmovement.com reports that activists in roughly 100 cities across the U.S. are hoping to replicate that resolution with the goal of decriminalizing certain psychedelic substances through ballot initiatives and legislative action at the local level.

Magic Mushrooms Showing High Levels of Psychological Benefits

2020 has been a big year for psilocybin mushrooms so far.

While the federal government still classifies it as dangerous, clinical evidence reveals that it does hold medicinal and therapeutic properties for the treatment of depression, alcohol addiction and many psychological disorders.

Experts at Johns Hopkins recently launched the Center for Psychedelic and Consciousness Research, for example. The U.S. FDA granted "breakthrough status" to COMPASS Pathways' psilocybin-assisted therapy just last year, which allows the FDA assist in the development of a promising drug to treat serious illnesses.

Researchers at New York University found psilocybin mushrooms caused a "rapid and sustained" reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.

Plus, a one-time, single dose of the drug combined with therapy helped improve the emotional wellbeing of cancer patients for up to five years, say researchers at NYU Grossman School of Medicine, as highlighted by Science Focus. In fact, in a 2016 study, it was found that psilocybin helped produce immediate, substantial, and sustained improvements in anxiety and depression.

Six months after that study, 60% to 80% of study participants saw significant reductions in anxiety or depression, distress, and overall quality of life. Five years later, more than 70% of the participants said the therapy resulted in long-term positive life changes for them.

"Adding to evidence dating back as early as the 1950s, our findings strongly suggest that psilocybin therapy is a promising means of improving the emotional, psychological, and spiritual well-being of patients with life-threatening cancer," said lead researcher Stephen Ross, as quoted by Science Focus. "This approach has the potential to produce a paradigm shift in the psychological and existential care of patients with cancer, especially those with terminal illness."

Yield Growth Corporation is a Major Beneficiary of Mushroom Story

"With increasing awareness around the therapeutic potential of mushrooms, I expect to see this trend continuing, and we are preparing to meet the potential future demand for these products with Flourish Mushroom Labs," says Yield Growth CEO Penny White. "With more dollars being put behind studying mushrooms for therapeutic use, I expect we will see more and more action to decriminalize psilocybin. We believe we are at the forefront of a true renaissance in therapeutic, plant-based medicine."

To date, Yield Growth has made substantial headway with the sprouting mushroom story.

Just recently, the company announced that subsidiary Flourish Mushroom Labs Inc. entered into a binding letter of intent with Acres Agricultural Canada Corp. to jointly form a company in Saint Vincent and the Grenadines, Acres Flourish Labs (SVG) Ltd. to build a laboratory for the cultivation of psilocybin mushrooms and for research and development into compounds and therapeutic use of psychedelic mushrooms.

The agreement contemplates that the proposed research and development of psilocybin for therapeutic use is within the purview of St. Vincent's Plant Breeders' Protection Bill, 2019 and the wider establishment of a viable and sustainable modern medicinal industry in St. Vincent and the Grenadines. The proposing parties are aware of and keenly interested in the conducive climatic conditions as exist in Saint Vincent for the controlled cultivation of psilocybin mushrooms, coupled with the existing offshore medical academic programs which can create an ideal environment for the advancement of the necessary scientific studies in Saint Vincent.

"We are very excited to be the first publicly traded company to announce a legal path to cultivate and research psychedelic mushrooms," says Yield Growth and Flourish CEO Penny White. "There is a renaissance of psychedelic medicine for which investor interest could go viral at any time. We are planning to enter this space with first mover advantage to deliver value to our shareholders."

In addition, Flourish Mushroom Labs Inc. completed the acquisition of a catalogue of mushroom formulas as the foundation of a mushroom edibles business. The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer's choice.

The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.

"Our research indicates that edible mushrooms are in a period of high growth," says Yield Growth CEO Penny White. "Yield Growth intends to add to its cannabis wellness assets through acquisitions in companies. Edible Mushrooms may experience hyper-growth as the movement to decriminalize psilocybin (magic mushrooms) grows, similar to how the popularity of hemp has grown with the legalization of cannabis."

For more information, visit the company's website at https://yieldgrowth.com.

About MarijuanaStox

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
2818047972
ty@marijuanastox.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52351

info